Standard Cosentyx Dosing for Adults
Cosentyx (secukinumab) dosing varies by condition. For plaque psoriasis, psoriatic arthritis, or ankylosing spondylitis, adults start with 300 mg subcutaneous injection at weeks 0, 1, 2, 3, then 300 mg every 4 weeks. For non-radiographic axial spondyloarthritis or enthesitis-related arthritis, it's 150 mg at the same intervals, increasing to 300 mg if needed. Crohn's disease uses 300 mg at weeks 0, 1, 2, 3, then every 4 weeks, or 600 mg induction for some cases.
Dosage Adjustments for Weight or Response
Increase to 300 mg every 4 weeks if 150 mg is inadequate for psoriatic arthritis, axial spondyloarthritis, or enthesitis-related arthritis in patients under 50 kg or with poor response. No routine weight-based adjustments otherwise, but pediatric patients (2+ years, ≥15 kg) for enthesitis-related arthritis use 75 mg if 15-50 kg or 150 mg if >50 kg, every 4 weeks after loading.
Adjustments for Hepatic or Renal Impairment
No dosage changes needed for mild to moderate hepatic or renal impairment. Data is limited for severe cases; use caution and monitor.
Interruptions and Missed Doses
If a dose is missed, administer as soon as possible if within 5 days of schedule, then resume. Beyond 5 days or if >5 days late, restart loading doses (300 mg weeks 0, 1, 2, 3) for psoriasis-related indications.
When to Permanently Discontinue
Stop Cosentyx if serious infection develops, active inflammatory bowel disease (for non-Crohn's indications), or hypersensitivity occurs. Reduce frequency or discontinue if neutropenia (ANC <1,000/mm³) or thrombocytopenia (<100,000/mm³) arises, resuming only after resolution.
For full details, consult the prescribing information or a healthcare provider, as adjustments depend on individual factors like concurrent infections or lab results.